Peijia Medical Limited

HKSE 9996.HK

Peijia Medical Limited Debt to Equity Ratio for the year ending December 31, 2023: 0.10

Peijia Medical Limited Debt to Equity Ratio is 0.10 for the year ending December 31, 2023, a 94.49% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Peijia Medical Limited Debt to Equity Ratio for the year ending December 31, 2022 was 0.05, a 1,879.19% change year over year.
  • Peijia Medical Limited Debt to Equity Ratio for the year ending December 31, 2021 was 0.00, a -22.15% change year over year.
  • Peijia Medical Limited Debt to Equity Ratio for the year ending December 31, 2020 was 0.00, a 176.69% change year over year.
  • Peijia Medical Limited Debt to Equity Ratio for the year ending December 31, 2019 was -0.00, a 83.96% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
SV Wall Street
HKSE: 9996.HK

Peijia Medical Limited

CEO Dr. Yi Zhang
IPO Date May 15, 2020
Location China
Headquarters 8 Zhongtian Street
Employees 1,050
Sector Health Care
Industries
Description

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.

Similar companies

9926.HK

Akeso, Inc.

USD 7.68

-4.49%

9969.HK

InnoCare Pharma Limited

USD 0.73

0.16%

9997.HK

Kangji Medical Holdings Limited

USD 0.82

2.23%

StockViz Staff

January 31, 2025

Any question? Send us an email